A Human Renal Proximal Tubule Cell Line with Stable Organic Anion Transporter 1 and 3 Expression Predictive for Antiviral-Induced Toxicity

AAPS Journal

Volumn 18, Issue 2, 2016, Pages 465-475

  Nieskens, Tom T G ^a   Peters, Janny G P ^a   Schreurs, Marieke J ^a   Smits, Niels ^a   Woestenenk, Rob ^b   Jansen, Katja ^a   van der Made, Thom K ^a   Röring, Melanie ^a   Hilgendorf, Constanze ^c   Wilmer, Martijn J ^a   Masereeuw, Rosalinde ^a,d  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ASTRAZENECA R AND D   (Sweden)

^d UTRECHT UNIVERSITY   (Netherlands)

Author keywords

antivirals; drug drug interactions; nephrotoxicity; organic anion transport; proximal tubule epithelial cell

Indexed keywords

4 AMINOHIPPURIC ACID; ADEFOVIR; CIDOFOVIR; CIMETIDINE; DICLOFENAC; ESTRONE SULFATE; FUROSEMIDE; ORGANIC ANION TRANSPORTER; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 3; PROBENECID; TENOFOVIR; ZIDOVUDINE; ADENINE; ANTIVIRUS AGENT; CYTOSINE; PHOSPHONIC ACID DERIVATIVE;

ACUTE KIDNEY FAILURE; ANTIVIRAL INDUCED TOXICITY; ARTICLE; CELL VIABILITY; CYTOTOXICITY; DRUG INDUCED NEPHROTOXICITY; DRUG SCREENING; EPITHELIUM CELL; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; HUMAN; IN VITRO STUDY; KIDNEY PROXIMAL TUBULE; NEPHROTOXICITY; PROTEIN EXPRESSION; TOXICITY; 3T3 CELL LINE; ANALOGS AND DERIVATIVES; ANIMAL; BIOSYNTHESIS; CELL LINE; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECTS; FORECASTING; GENE EXPRESSION REGULATION; HEK293 CELL LINE; METABOLISM; MOUSE; PHYSIOLOGY; TRANSFORMED CELL LINE;

3T3 CELLS; ADENINE; ANIMALS; ANTIVIRAL AGENTS; CELL LINE; CELL LINE, TRANSFORMED; CELL SURVIVAL; CYTOSINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FORECASTING; GENE EXPRESSION REGULATION; HEK293 CELLS; HUMANS; KIDNEY TUBULES, PROXIMAL; MICE; ORGANIC ANION TRANSPORT PROTEIN 1; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; ORGANOPHOSPHONATES;

EID: 84959541935     PISSN: None     EISSN: 15507416     Source Type: Journal    
DOI: 10.1208/s12248-016-9871-8     Document Type: Article

References (64)

1. Tiong HY, Huang P, Xiong S, Li Y, Vathsala A, Zink D. Drug-induced nephrotoxicity: clinical impact and preclinical in vitro models. Mol Pharm. 2014;11(7):1933–48.
2. Redfern WS, Ewart L, Hammond TG, Bialecki R, Kinter L, Lindgren S. Impact and frequency of different toxicities throughout the pharmaceutical life cycle. Toxicologist. 2010;114:1081.
3. Guengerich FP. Mechanisms of drug toxicity and relevance to pharmaceutical development. Drug Metab Pharmacokinet. 2011;26(1):3–14.
4. Gundert-Remy U, Bernauer U, Blomeke B, Doring B, Fabian E, Goebel C, et al. Extrahepatic metabolism at the body’s internal-external interfaces. Drug Metab Rev. 2014;46(3):291–324.
5. Wang L, Sweet DH. Renal organic anion transporters (SLC22 family): expression, regulation, roles in toxicity, and impact on injury and disease. AAPS J. 2013;15(1):53–69.
6. Burckhardt G, Burckhardt BC. In vitro and in vivo evidence of the importance of organic anion transporters (OATs) in drug therapy. Handb Exp Pharmacol. 2011;201:29–104.
7. Masereeuw R, Russel FG. Therapeutic implications of renal anionic drug transporters. Pharmacol Ther. 2010;126(2):200–16.
8. Motohashi H, Inui K. Organic cation transporter OCTs (SLC22) and MATEs (SLC47) in the human kidney. AAPS J. 2013;15(2):581–8.
9. Konig J, Muller F, Fromm MF. Transporters and drug-drug interactions: important determinants of drug disposition and effects. Pharmacol Rev. 2013;65(3):944–66.
10. Morrissey KM, Stocker SL, Wittwer MB, Xu L, Giacomini KM. Renal transporters in drug development. Annu Rev Pharmacol Toxicol. 2013;53:503–29.
11. Izzedine H, Harris M, Perazella MA. The nephrotoxic effects of HAART. Nat Rev Nephrol. 2009;5(10):563–73.
12. Lewis W, Day BJ, Copeland WC. Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective. Nat Rev Drug Discov. 2003;2(10):812–22.
13. De Clercq E. Antiviral drugs in current clinical use. J Clin Virol. 2004;30(2):115–33.
14. Tourret J, Deray G, Isnard-Bagnis C. Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword? J Am Soc Nephrol. 2013;24(10):1519–27.
15. Kohler JJ, Hosseini SH, Green E, Abuin A, Ludaway T, Russ R, et al. Tenofovir renal proximal tubular toxicity is regulated by OAT1 and MRP4 transporters. Lab Investig. 2011;91(6):852–8.
16. Takeda M, Khamdang S, Narikawa S, Kimura H, Kobayashi Y, Yamamoto T, et al. Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther. 2002;300(3):918–24.
17. Cihlar T, Lin DC, Pritchard JB, Fuller MD, Mendel DB, Sweet DH. The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1. Mol Pharmacol. 1999;56(3):570–80.
18. Lacy SA, Hitchcock MJ, Lee WA, Tellier P, Cundy KC. Effect of oral probenecid coadministration on the chronic toxicity and pharmacokinetics of intravenous cidofovir in cynomolgus monkeys. Toxicol Sci. 1998;44(2):97–106.
19. Kearney BP, Flaherty JF, Shah J. Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clin Pharmacokinet. 2004;43(9):595–612.
20. Vigouroux C, Bastard JP, Capeau J. Emerging clinical issues related to management of multiorgan comorbidities and polypharmacy. Curr Opin HIV AIDS. 2014;9(4):371–8.
21. Wilmer MJ, Saleem MA, Masereeuw R, Ni L, van der Velden TJ, Russel FG, et al. Novel conditionally immortalized human proximal tubule cell line expressing functional influx and efflux transporters. Cell Tissue Res. 2010;339(2):449–57.
22. Schophuizen CM, Wilmer MJ, Jansen J, Gustavsson L, Hilgendorf C, Hoenderop JG, et al. Cationic uremic toxins affect human renal proximal tubule cell functioning through interaction with the organic cation transporter. Pflugers Arch - Eur J Physiol. 2013;465(12):1701–14.
23. Mutsaers HA, Wilmer MJ, Reijnders D, Jansen J, van den Broek PH, Forkink M, et al. Uremic toxins inhibit renal metabolic capacity through interference with glucuronidation and mitochondrial respiration. Biochim Biophys Acta. 2013;1832(1):142–50.
24. Jansen J, Schophuizen CM, Wilmer MJ, Lahham SH, Mutsaers HA, Wetzels JF, et al. A morphological and functional comparison of proximal tubule cell lines established from human urine and kidney tissue. Exp Cell Res. 2014;323(1):87–99.
25. Saleem MA, O’Hare MJ, Reiser J, Coward RJ, Inward CD, Farren T, et al. A conditionally immortalized human podocyte cell line demonstrating nephrin and podocin expression. J Am Soc Nephrol. 2002;13(3):630–8.
26. Moghadasali R, Mutsaers HA, Azarnia M, Aghdami N, Baharvand H, Torensma R, et al. Mesenchymal stem cell-conditioned medium accelerates regeneration of human renal proximal tubule epithelial cells after gentamicin toxicity. Exp Toxicol Pathol. 2013;65(5):595–600.
27. Cihlar T, Ho ES. Fluorescence-based assay for the interaction of small molecules with the human renal organic anion transporter 1. Anal Biochem. 2000;283(1):49–55.
28. Jung KY, Takeda M, Kim DK, Tojo A, Narikawa S, Yoo BS, et al. Characterization of ochratoxin A transport by human organic anion transporters. Life Sci. 2001;69(18):2123–35.
29. Deguchi T, Kusuhara H, Takadate A, Endou H, Otagiri M, Sugiyama Y. Characterization of uremic toxin transport by organic anion transporters in the kidney. Kidney Int. 2004;65(1):162–74.
30. Srimaroeng C, Jutabha P, Pritchard JB, Endou H, Chatsudthipong V. Interactions of stevioside and steviol with renal organic anion transporters in S2 cells and mouse renal cortical slices. Pharm Res. 2005;22(6):858–66.
31. Cha SH, Sekine T, Fukushima JI, Kanai Y, Kobayashi Y, Goya T, et al. Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol. 2001;59(5):1277–86.
32. Chu XY, Bleasby K, Yabut J, Cai X, Chan GH, Hafey MJ, et al. Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein. J Pharmacol Exp Ther. 2007;321(2):673–83.
33. Hasannejad H, Takeda M, Taki K, Shin HJ, Babu E, Jutabha P, et al. Interactions of human organic anion transporters with diuretics. J Pharmacol Exp Ther. 2004;308(3):1021–9.
34. Khamdang S, Takeda M, Shimoda M, Noshiro R, Narikawa S, Huang XL, et al. Interactions of human- and rat-organic anion transporters with pravastatin and cimetidine. J Pharmacol Sci. 2004;94(2):197–202.
35. Motohashi H, Uwai Y, Hiramoto K, Okuda M, Inui K. Different transport properties between famotidine and cimetidine by human renal organic ion transporters (SLC22A). Eur J Pharmacol. 2004;503(1-3):25–30.
36. Khamdang S, Takeda M, Noshiro R, Narikawa S, Enomoto A, Anzai N, et al. Interactions of human organic anion transporters and human organic cation transporters with nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther. 2002;303(2):534–9.
37. Mulato AS, Ho ES, Cihlar T. Nonsteroidal anti-inflammatory drugs efficiently reduce the transport and cytotoxicity of adefovir mediated by the human renal organic anion transporter 1. J Pharmacol Exp Ther. 2000;295(1):10–5.
38. Kimura N, Masuda S, Tanihara Y, Ueo H, Okuda M, Katsura T, et al. Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet. 2005;20(5):379–86.
39. Mandikova J, Volkova M, Pavek P, Cesnek M, Janeba Z, Kubicek V, et al. Interactions with selected drug renal transporters and transporter-mediated cytotoxicity in antiviral agents from the group of acyclic nucleoside phosphonates. Toxicology. 2013;311(3):135–46.
40. Barditch-Crovo P, Toole J, Hendrix CW, Cundy KC, Ebeling D, Jaffe HS, et al. Anti-human immunodeficiency virus (HIV) activity, safety, and pharmacokinetics of adefovir dipivoxil (9-[2-(bis-pivaloyloxymethyl)-phosphonylmethoxyethyl]adenine) in HIV-infected patients. J Infect Dis. 1997;176(2):406–13.
41. Cundy KC, Barditch-Crovo P, Walker RE, Collier AC, Ebeling D, Toole J, et al. Clinical pharmacokinetics of adefovir in human immunodeficiency virus type 1-infected patients. Antimicrob Agents Chemother. 1995;39(11):2401–5.
42. Wachsman M, Petty BG, Cundy KC, Jaffe HS, Fisher PE, Pastelak A, et al. Pharmacokinetics, safety and bioavailability of HPMPC (cidofovir) in human immunodeficiency virus-infected subjects. Antivir Res. 1996;29(2-3):153–61.
43. Cundy KC, Petty BG, Flaherty J, Fisher PE, Polis MA, Wachsman M, et al. Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 1995;39(6):1247–52.
44. Cihlar T, Laflamme G, Fisher R, Carey AC, Vela JE, Mackman R, et al. Novel nucleotide human immunodeficiency virus reverse transcriptase inhibitor GS-9148 with a low nephrotoxic potential: characterization of renal transport and accumulation. Antimicrob Agents Chemother. 2009;53(1):150–6.
45. Kearney BP, Ramanathan S, Cheng AK, Ebrahimi R, Shah J. Systemic and renal pharmacokinetics of adefovir and tenofovir upon coadministration. J Clin Pharmacol. 2005;45(8):935–40.
46. Flynn PM, Mirochnick M, Shapiro DE, Bardeguez A, Rodman J, Robbins B, et al. Pharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infants. Antimicrob Agents Chemother. 2011;55(12):5914–22.
47. Moore KH, Raasch RH, Brouwer KL, Opheim K, Cheeseman SH, Eyster E, et al. Pharmacokinetics and bioavailability of zidovudine and its glucuronidated metabolite in patients with human immunodeficiency virus infection and hepatic disease (AIDS Clinical Trials Group protocol 062). Antimicrob Agents Chemother. 1995;39(12):2732–7.
48. Huang SH, Zhang, L. Drug interaction studies - study design, data analysis, implications for dosing, and labeling recommendations. In: Services HaH (ed.) Silver Spring, MD 2012. p. 75.
49. Zhang X, Wang R, Piotrowski M, Zhang H, Leach KL. Intracellular concentrations determine the cytotoxicity of adefovir, cidofovir and tenofovir. Toxicol in Vitro. 2015;29(1):251–8.
50. Lash LH, Putt DA, Cai H. Membrane transport function in primary cultures of human proximal tubular cells. Toxicology. 2006;228(2-3):200–18.
51. Brown CD, Sayer R, Windass AS, Haslam IS, De Broe ME, D’Haese PC, et al. Characterisation of human tubular cell monolayers as a model of proximal tubular xenobiotic handling. Toxicol Appl Pharmacol. 2008;233(3):428–38.
52. Wieser M, Stadler G, Jennings P, Streubel B, Pfaller W, Ambros P, et al. hTERT alone immortalizes epithelial cells of renal proximal tubules without changing their functional characteristics. Am J Physiol Renal Physiol. 2008;295(5):F1365–75.
53. Aschauer L, Carta G, Vogelsang N, Schlatter E, Jennings P. Expression of xenobiotic transporters in the human renal proximal tubule cell line RPTEC/TERT1. Toxicol In Vitro. 2015;30(1 Pt A):95–105.
54. Wang L, Sweet DH. Potential for food–drug interactions by dietary phenolic acids on human organic anion transporters 1 (SLC22A6), 3 (SLC22A8), and 4 (SLC22A11). Biochem Pharmacol. 2012;84(8):1088–95.
55. Imaoka T, Kusuhara H, Adachi M, Schuetz JD, Takeuchi K, Sugiyama Y. Functional involvement of multidrug resistance-associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir. Mol Pharmacol. 2007;71(2):619–27.
56. Varma MV, Feng B, Obach RS, Troutman MD, Chupka J, Miller HR, et al. Physicochemical determinants of human renal clearance. J Med Chem. 2009;52(15):4844–52.
57. Blum MR, Liao SH, Good SS, de Miranda P. Pharmacokinetics and bioavailability of zidovudine in humans. Am J Med. 1988;85(2a):189–94.
58. Lee H, Hanes J, Johnson KA. Toxicity of nucleoside analogues used to treat AIDS and the selectivity of the mitochondrial DNA polymerase. Biochemistry. 2003;42(50):14711–9.
59. Nigam SK. What do drug transporters really do? Nat Rev Drug Discov. 2015;14(1):29–44.
60. EMA. Guideline on the investigation of drug interactions. London: Agency EM; 2010. p. 38.
61. International Transporter C, Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, et al. Membrane transporters in drug development. Nat Rev Drug Discov. 2010;9(3):215–36.
62. McGuinness L. CRACK IT Challenge winners awarded £4.9 million to further their research London, UK: National Centre for the Replacement, Refinement and Reduction of Animals in Research; 2014 [cited 2015 14-05-2015]. Available from: https://www.nc3rs.org.uk/crackit-news/crack-it-challenge-winners-awarded-%C2%A349-million-further-their-research.
63. Chu X, Bleasby K, Evers R. Species differences in drug transporters and implications for translating preclinical findings to humans. Exp Opin Drug Metab Toxicol. 2013;9(3):237–52.
64. Bhatia SN, Ingber DE. Microfluidic organs-on-chips. Nat Biotechnol. 2014;32(8):760–72.